VEO Launches VisionOne AI Visual Field Platform in U.S.

VEO Ophthalmics has announced a strategic partnership with PeriVision, a Swiss-based medical technology company, to introduce the VisionOne VR Visual Field platform to the United States. This collaboration brings PeriVision’s patented AI-driven visual field-testing algorithm, known as SORS (Sequentially Optimized Reconstruction Strategy), to U.S. clinicians, offering a portable and efficient alternative to traditional perimetry methods.

VisionOne Platform Introduces AI-Enhanced Visual Field-Testing Capabilities

The VisionOne system integrates the SORS algorithm, which dynamically optimizes the sequence of visual field testing in real-time. This advanced approach is designed to:

• Reduce test duration

• Maintain high accuracy compared to gold-standard visual field methods

• Enhance test-retest reliability

VisionOne allows ophthalmologists and optometrists to perform visual field exams using portable VR headsets, providing patients with a more comfortable and accessible testing experience. Results are stored and analyzed on a secure, cloud-based analytics platform, with AI algorithms automating test guidance, interpretation, and quality control, streamlining workflows while enhancing clinical precision.

Addressing Workforce Shortages and Growing Demand

“Just last year, a publication estimated that from 2020 to 2035, the ophthalmology workforce is expected to shrink by more than 2,600 full-time equivalents (FTE), while demand will grow by around 5,000 FTE,” said Patrick Kessel, CEO of PeriVision.

“VisionOne addresses this drastically growing need for more efficient and patient-friendly ophthalmic testing. We are very excited to partner with VEO Ophthalmics to deliver our breakthrough technology to eye care professionals across the U.S.”

“VisionOne uniquely allows eye care professionals to reduce visual field testing time and maintain accuracy when diagnosing and monitoring glaucoma with advanced AI algorithms. We are very pleased to partner with PeriVision and bring this technology to eye care professionals to enhance patient care," said Ron Gilliland, President and CEO of VEO Ophthalmics.

Exclusive U.S. Distribution Agreement

Under the terms of the partnership, VEO Ophthalmics will hold exclusive distribution rights for the VisionOne platform in the U.S. The company will oversee the introduction, commercialization, and support of the solution across the American eye care market.